A Phase 2b, Study of Linsitinib in Subjects With Active, Moderate to Severe Thyroid Eye Disease (TED)

A Phase 2b, Study of Linsitinib in Subjects With Active, Moderate to Severe Thyroid Eye Disease (TED)
Conditions:   Thyroid Eye Disease;   Graves Orbitopathy;   Endocrine System Diseases;   Eye Diseases;   Thyroid Associated Ophthalmopathy;   Graves Ophthalmopathy;   Thyroid Diseases;   Orbital Diseases;   Proptosis;   IGF1R;   Exophthalmos;   Hashimoto
Interventions:   Drug: Linsitinib;   Drug: Placebo
Sponsor:   Sling Therapeutics, Inc.
**RECRUITING NOW**

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

July 23, 2022Comments OffClinicalTrials.gov | Endocrinology Clinical Trials | Endocrinology Studies | US National Library of Medicine
Comments